October 27, 2021

Despite repeated attempts to debunk misinformation about the anti-parasitic ivermectin as a  purported COVID-19 treatment, false claims about the drug persist online.

“NIH COVID Treatment Guidelines Approve Ivermectin,” reads an Oct. 21 Instagram post.

The post goes on to say that the National Institutes of Health made a “silent” update to a key website, indicating that ivermectin is one of the “antiviral agents that are approved or under evaluation for the treatment of COVID-19.”

The post was flagged as part of Facebook’s efforts to combat false news and misinformation on its News Feed. (Read more about our partnership with Facebook.)

Has the NIH approved ivermectin as a COVID-19 treatment? No.

The NIH is a central access point for much of the latest COVID-19 research — including research into treatments that are approved or being studied.

A page on the NIH website provides information about antiviral therapies that are being evaluated, or have been evaluated, as possible treatments for COVID-19. But the site makes clear that the NIH has not approved or recommended ivermectin to treat COVID-19.

“Remdesivir is the only Food and Drug Administration-approved drug for the treatment of COVID-19,” reads the NIH’s summary recommendations.

The page includes the language from the post — “Antiviral Drugs That Are Approved or Under Evaluation for the Treatment of COVID-19” — and was last updated on July 8. But it does not indicate that ivermectin is an approved treatment.

Here’s what it does say:

“There is insufficient evidence for the Panel to recommend either for or against the use of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin in the treatment of COVID-19.”

Another page of the site specifically about ivermectin says it more clearly:

“Ivermectin is not approved by the FDA for the treatment of any viral infection.”

The NIH’s ivermectin page says some randomized trials and studies of ivermectin in COVID-19 patients have shown “no benefits or worsening of disease,” while others showed varying levels of effectiveness, ranging from: “shorter time to resolution of disease manifestations that were attributed to COVID-19, greater reduction in inflammatory marker levels, shorter time to viral clearance, or lower mortality rates in patients who received ivermectin than in patients who received comparator drugs or placebo.”

A spokesperson for the NIH noted that the ivermectin page of the NIH COVID-19 Treatment Guidelines was last updated on Feb. 11, and the clinical data was updated July 19. The NIH “doesn’t silently update” its pages, she said.

“We update them regularly to ensure they are current,” the spokesperson said. “The date they are last updated is included on the page.”

For the COVID-19 Treatment Guidelines in particular, she said people can sign up for updates so they are notified whenever there is a change on the page.

In explaining why it decided not to recommend ivermectin as a treatment, the NIH’s COVID-19 Treatment Guidelines Panel said studies suggesting the drug was effective “had incomplete information and significant methodological limitations, which make it difficult to exclude common causes of bias.”

Clinical trials to assess the use of ivermectin to treat COVID-19 are “currently underway or in development,” according to the NIH.

Our ruling

A post claimed, “NIH COVID Treatment Guidelines Approve Ivermectin.”

The NIH includes ivermectin on a list of drugs that are being evaluated as COVID-19 possible treatments. But its Treatment Guidelines Panel has not recommended “for or against” the use of ivermectin to treat COVID-19, citing the need for more clinical trials.

We rate this claim False.

This fact check was originally published by PolitiFact, which is part of the Poynter Institute. It is republished here with permission. See the sources for this fact check here and more of their fact checks here.

Support high-integrity, independent journalism that serves democracy. Make a gift to Poynter today. The Poynter Institute is a nonpartisan, nonprofit organization, and your gift helps us make good journalism better.
Madison Czopek is a contributing writer for PolitiFact. She was a reporter for PolitiFact Missouri and a former public life reporter for the Columbia Missourian.…
Madison Czopek

More News

Looking back at a horrific week

Coverage of the police response and how politicians have responded, urgent questions about showing images, powerful late-night monologues, and more.

May 27, 2022
Back to News